ImmuVen (www.immuven.com) was awarded a Phase II Small Business Innovation Research (SBIR) grant totaling $1.68 million from the National Institute for Allergy and Infectious Disease (NIH) for continuing development of its therapeutic pipeline (IMV0123) against superantigens produced by methicillin-sensitive and methicillin-resistant Staphylococcal aureus. This award continues the work previously supported by a successfully completed Phase I SBIR grant.
ImmuVen's biotherapeutic approach to neutralizing superantigen toxicity is uniquely positioned to intervene in deaths and morbidity caused by superantigen production in a host of S. aureus infections including pneumonia and endocarditis. The goal of this award is to provide support for bringing IMV0123 through a pre-Investigational New Drug (IND) meeting with the Food and Drug Administration (FDA) in addition to completing major milestones in the preclinical development of the therapeutic.
Study finds connection between air pollution and childhood peanut allergies